Evaluation of 626 in Healthy Adult Subjects

Phase 1 Completed 50 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose phase I clinical study to evaluate the safety, tolerability, PK and immunogenicity of SSGJ-626 in healthy adult subjects after single subcutaneous injection.

Timeline

Start: 2024-12-02
Primary completion: 2025-08-13
Completion: 2025-08-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	626	Unknown	—	Subcutaneous

Indications

No indication recorded.